PhotonPharma Inc, a developer of autologous cancer immunotherapies, announced on Thursday the appointment of William Warren, Ph.D. to its board of directors.
PhotonPharma says that Dr. Warren brings more than three decades of experience in biotechnology innovation, vaccine development, and successful entrepreneurship to guide the company's strategic initiatives and growth trajectory.
Most recently, Dr. Warren served in multiple senior leadership roles at Sanofi Vaccines R&D, including head of Innovation, leading a virtual biotech to advance next-generation influenza vaccines, and head of Global Antigen Design, where his group was responsible for antigen designs to advance projects, invigorate an innovative culture, and explore biology and technology interfaces.
Prior to Sanofi, Dr. Warren was CEO and co-founder of VaxDesign Corporation, which he led through its acquisition by Sanofi in 2010. He also co-founded nScrypt Inc, a company specialising in advanced 3D printing and bioprinting systems, and was a managing partner of Sciperio Inc, an innovative high-technology development company.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Formation Bio acquires worldwide rights to FHND5032 from CTFH
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
Almirall receives China approval for Seysara to treat moderate-to-severe acne